Evaluating only Xilio Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
FUNDING
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Xilio Therapeutics developed tumor-selective cytokine therapies — engineered versions of IL-2 and IL-12 designed to activate only within the immunosuppressive tumor microenvironment. The company raised $100M+ and listed on Nasdaq in 2021. Phase 1 clinical data for its lead program XTX101 showed safety but insufficient tumor-selective efficacy signals to justify Phase 2 advancement. In a challenged biotech funding environment, the company could not raise a follow-on round based on Phase 1 data alone and terminated its clinical programs, selling remaining IP and assets to a strategic acquirer.
Lesson
“Oncology biotech must secure follow-on capital commitments before Phase 1 readout — the window between data and market reaction is too narrow for fundraising.”